Clinical Trials Logo

Granulomatosis With Polyangiitis clinical trials

View clinical trials related to Granulomatosis With Polyangiitis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05376319 Terminated - Clinical trials for Microscopic Polyangiitis

PR3-AAV Resilient Remission or PRRR

Start date: June 30, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).

NCT ID: NCT03712345 Terminated - Clinical trials for Microscopic Polyangiitis (MPA)

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.

NCT ID: NCT02626845 Terminated - Clinical trials for Granulomatosis With Polyangiitis (Wegener's Granulomatosis)

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

RENTGPA
Start date: December 2015
Phase: Phase 4
Study type: Interventional

This is a phase IV, single-center, randomized, placebo-controlled pilot study that will evaluate the efficacy of rituximab at inducing otolaryngologic remission in GPA patients with active otolaryngologic disease.

NCT ID: NCT02474888 Terminated - Clinical trials for Microscopic Polyangiitis

Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis

MONITUX
Start date: September 15, 2015
Phase:
Study type: Observational

The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels could be an interesting tool in the follow-up of ANCA-associated vasculitis patients. All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or the relapse of a known ANCA-associated vasculitis, in which the decision to start an induction regimen with rituximab has been taken, will be included. Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.

NCT ID: NCT01586858 Terminated - Clinical trials for Microscopic Polyangiitis

Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study

RAVELOS
Start date: May 2012
Phase: N/A
Study type: Observational

Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscopic polyangiitis. Because it is a relatively new medication, the long-term safety and efficacy of this drug is not yet clear. This study proposes to follow patients who were enrolled in the RAVE study to determine if treatment with rituximab influences long-term outcomes.